Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
39,900
-5,400 (-11.92%)
Last updated: Oct 10, 2025, 2:46 PM KST
-11.92%
Market Cap574.49B
Revenue (ttm)n/a
Net Income (ttm)-39.44B
Shares Out14.38M
EPS (ttm)-2,780.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8,446,067
Average Volume82,517
Open45,300
Previous Close45,300
Day's Range32,700 - 45,300
52-Week Range19,390 - 45,500
Betan/a
RSI48.22
Earnings DateNov 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.